959236-97-6

Usage

Uses

Used in Pharmaceutical Industry:
2-METHYLTHIO-4-BROMOPYRIMIDINE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 2-METHYLTHIO-4-BROMOPYRIMIDINE serves as an intermediate in the production of agrochemicals. Its reactivity and structural features make it suitable for the creation of compounds that can be used in crop protection and other agricultural applications.
Used in Organic Synthesis:
2-METHYLTHIO-4-BROMOPYRIMIDINE is utilized as a building block in organic synthesis. Its presence in the synthesis of complex organic molecules highlights its importance in the field of organic chemistry, where it can be used to construct a wide range of chemical entities with diverse applications.
Safety Note:
Due to its highly reactive nature, 2-METHYLTHIO-4-BROMOPYRIMIDINE should be handled with caution in laboratory settings to ensure the safety of researchers and the integrity of experiments. Proper handling protocols and safety measures should be strictly followed to mitigate any potential risks associated with 2-METHYLTHIO-4-BROMOPYRIMIDINE.

InChI:InChI=1/C5H5BrN2S/c1-9-5-7-3-2-4(6)8-5/h2-3H,1H3

Upstream product

• 49844-90-8 4-Chloro-2-methylthiopyrimidine 
• 5751-20-2 2-Methylthiouracil 

Downstream Products

• 1208538-52-6 4-bromo-2-(methylsulfonyl)pyrimidine 
• 1453854-80-2 1-(2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1H)-one 

Relevant academic research and scientific papers

INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor

3,6-Disubstituted imidazo[1,2-b]pyridazine derivatives were synthesized to identify new inhibitors of various eukaryotic kinases, including mammalian and protozoan kinases. Among the imidazo[1,2-b]pyridazines tested as kinase inhibitors, several derivatives were selective for DYRKs and CLKs, with IC50?50?=?82?nM), CLK4 (IC50?=?44?nM), DYRK1A (IC50?=?50?nM), and PfCLK1 (IC50?=?32?nM). The compounds were also tested against Leishmania amazonensis. Several compounds showed anti-leishmanial activity at rather high (10?μM) concentration, but were not toxic at 1?μM or 10?μM, as judged by viability assays carried out using a neuroblastoma cell line.

Structure–Activity Relationships of 2-Sufonylpyrimidines as Quorum-Sensing Inhibitors to Tackle Biofilm Formation and eDNA Release of Pseudomonas aeruginosa

Drug-resistant Pseudomonas aeruginosa (PA) strains are on the rise, making treatment with current antibiotics ineffective. Hence, circumventing resistance or restoring the activity of antibiotics by novel approaches is of high demand. Targeting the Pseudomonas quinolone signal quorum sensing (PQS-QS) system is an intriguing strategy to abolish PA pathogenicity without affecting the viability of the pathogen. Herein we report the structure–activity relationships of 2-sulfonylpyrimidines, which were previously identified as dual-target inhibitors of the PQS receptor PqsR and the PQS synthase PqsD. The SAR elucidation was guided by a combined approach using ligand efficiency and ligand lipophilicity efficiency to select the most promising compounds. In addition, the most effective inhibitors were rationally modified by the guidance of QSAR using Hansch analyses. Finally, these inhibitors showed the capacity to decrease biofilm mass and extracellular DNA, which are important determinants for antibiotic resistance.

Synthesis of cytimidine through a one-pot copper-mediated amidation cascade

A concise synthesis of cytimidine was developed utilizing tandem Cu-mediated N-aryl amidations followed by global deprotection. This sequence exploits a regioselective coupling of an iodobenzamide with a halopyrimidine that allows the union of three fragments in a single synthetic manipulation and will permit the efficient and rapid diversification of the cytimidine core.